Human PBMCs, Super Donor
RedyBio has discovered a set of biomarkers and screening methods to identify the super donors for potential allogeneic CAR-T cell therapy. CAR-T cells generated using super donor PBMCs elicit excellent in vivo persistence and superior anti-tumor efficacy against liquid and solid tumors, compared to CAR-T cells generated from regular donor PBMCs.
RedyBio has discovered a set of biomarkers and screening methods to identify the super donors for potential allogeneic CAR-T cell therapy. CAR-T cells generated using super donor PBMCs elicit excellent in vivo persistence and superior anti-tumor efficacy against liquid and solid tumors, compared to CAR-T cells generated from regular donor PBMCs.
RedyBio has discovered a set of biomarkers and screening methods to identify the super donors for potential allogeneic CAR-T cell therapy. CAR-T cells generated using super donor PBMCs elicit excellent in vivo persistence and superior anti-tumor efficacy against liquid and solid tumors, compared to CAR-T cells generated from regular donor PBMCs.